Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World J Gastroenterol 2013; 19(47): 8940-8948 [PMID: 24379619 DOI: 10.3748/wjg.v19.i47.8940]
Corresponding Author of This Article
Tatsuo Kanda, MD, PhD, Associate Professor, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. kandat-cib@umin.ac.jp
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 2 Clinical characteristics of hepatitis C virus genotype 1b-infected patients in sequence analysis study of the hepatitis C virus NS3 region
No. of patients (men/women)
88 (43/45)
Age (yr)
55 ± 14
HCV RNA levels (low/high)
1/87
ALT (IU/L)
67 ± 44
WBC (x 103/mcL)
5.2 ± 1.5
Hemoglobin (g/dL)
14 ± 1.2
Platelet counts (x 104/mcL)
20 ± 18
IL28B rs8099917, TT/TG/GG/unknown
45/29/0/14
Table 3 Naturally occurring pre-existing resistance amino acid mutations in the hepatitis C virus NS3 regions of 28 protease inhibitor-naive patients infected with hepatitis C virus genotype 1
PatientNo.
V36
T54
V55
Q80
R155
A156
D168
V170Y/N/L
A/M
S
A
L
K/T/Q
S/T/V
N
Y
N
L
31
S
L
95
L
15
L
17
L
24
L
26
S
L
29
S
81
S
L
61
Y
72
Y
11
L
12
L
2
Y
53
L
55
L
66
L
84
L
85
L
110
L
112
Y
114
S
L
100
L
101
N
107
N
111
N
99
L
92
L
97
S
L
N
Table 4 Nucleotide changes were required for amino acid substitutions at position 155 of hepatitis C virus NS3 among hepatitis C virus genotype 1 samples
Amino acid at position 155
HCV genotype 1a
HCV genotype 1b
R
AGG
CGG
K
AAG
AAG
T
ACG
ACG
S
AGC
AGC
I
ATC
ATC
Citation: Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World J Gastroenterol 2013; 19(47): 8940-8948